Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a method to predict which patients with a primary liver cancer called hepatocellular ...
Jul 15, 2026
0
8
The first-in-patient, single-arm ARC-20 clinical trial, led by Dana-Farber Cancer Institute's Toni K. Choueiri, MD, has evaluated casdatifan, a next-generation HIF-2α inhibitor, as monotherapy for metastatic clear cell renal ...
Jul 1, 2026
0
4
An experimental drug combination may help overcome treatment resistance in advanced kidney cancer, according to early results from a first-in-human clinical trial led by Mayo Clinic researchers.
Jun 5, 2026
0
3
An oral combination treatment may prevent the progression of advanced leiomyosarcoma, one of the most common subtypes of soft tissue sarcoma, according to a recent study published in The Lancet Oncology. "These findings support ...
Feb 10, 2026
0
42
Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC)—a ...
Oct 20, 2025
0
19
The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced neuroendocrine tumors, offering a new standard of care for this ...
Mar 31, 2025
0
9
Researchers at the Icahn School of Medicine at Mount Sinai have made an important discovery that could help doctors choose better treatments for patients with recurrent endometrial cancer. Their study, published in the Journal ...
Mar 4, 2025
0
29
In the open-label phase 2 LITESPARK-003 study, led by Dana-Farber Cancer Institute's Toni Choueiri, MD, researchers investigated for the first time the combination of cabozantinib, an anti-angiogenic agent, plus belzutifan, ...
Jan 17, 2025
0
28
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo (nivolumab) indications.
Jan 3, 2025
0
28
The Alliance for Clinical Trials in Oncology today announced that final results will be presented at ESMO 2024 from CABINET (A021602), a phase III trial evaluating cabozantinib compared with placebo in two cohorts of patients ...
Sep 16, 2024
0
40
